



4 September 2023

SomnoMed Limited ACN 003 255 221 (ASX:SOM) – Successful completion of institutional placement and institutional component of Entitlement Offer

SomnoMed Limited (**SomnoMed** or **Company**) is today pleased to announce the successful completion of the institutional placement (“**Placement**”) and the institutional component (“**Institutional Entitlement Offer**”) of its 1 for 3.82 accelerated non-renounceable entitlement offer of new fully paid ordinary shares (**New Shares**) in the Company (**Entitlement Offer**).

The Placement and Institutional Entitlement Offer closed on Friday, 1st September 2023.

Approximately 11.7 million New Shares will be issued to successful applicants under the Institutional Entitlement Offer at an issue price of \$0.60 per New Share (**Offer Price**), raising an aggregate of approximately A\$7.0 million. The Institutional Entitlement Offer had strong support from existing domestic and international institutional shareholders with a take-up rate of approximately 97%. The Placement also had strong support from both new and existing institutional shareholders with approximately 4.2 million New Shares to be issued, raising an aggregate of A\$2.5 million.

The shortfall of A\$251,309.40 (418,849 shares) from the Institutional Entitlement Offer has been placed to certain new and existing institutional investors. No shortfall shares were allocated to the sub-underwriter, TDM.

The use of proceeds of the Entitlement Offer was outlined in the Company's announcement on Thursday 31st August, and included working capital and a reduction in the balance of the Epsilon Direct Lending debt facility. As a result of the successful completion of the Placement and Institutional Entitlement Offer, SomnoMed's ordinary shares (**Shares**) will recommence normal trading on an ex-entitlement basis from the opening of the market Monday, 4 September 2023.

Shares issued pursuant to the Institutional Entitlement Offer and Placement will rank equally with existing Shares on issue with effect from their date of issue. New Shares subscribed for under the Institutional Entitlement Offer and Placement are expected to be settled on Thursday, 7 September 2023 and to be issued and commence trading on the ASX on Friday, 8 September 2023.

Retail Entitlement Offer

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) will approximately raise a further \$5.7 million.

The Retail Entitlement Offer is available to shareholders whose address is in Australia, New Zealand Hong Kong or Singapore as recorded with the Company's share registry as at 7.00pm (Sydney, Australia time) on Friday, Monday 4 September 2023 (**Record Date**) (**Eligible Retail Shareholders**).

Eligible Retail Shareholders are being invited to subscribe for 1 Share for every 3.82 Shares held on the Record Date at the Offer Price of \$0.60 per Share. The offer ratio and offer price for Shares under the Retail Entitlement Offer are the same as for the Institutional Entitlement Offer. Eligible Retail Shareholders who take up their entitlement in full under the Retail Entitlement Offer may elect to apply for that number of Additional New Shares in excess of their Entitlement which represents 100% of their Entitlement (**Additional New Shares**).

The Retail Entitlement Offer will open on Thursday, 7 September 2023 and close at 5.00pm (Sydney, Australia time) on Thursday, 21 September 2023 (unless extended or withdrawn).

Eligible Retail Shareholders wishing to participate in the Retail Entitlement Offer should carefully read the retail offer booklet and accompanying personalised entitlement and acceptance form, which are expected to be dispatched on Thursday, 7 September 2023. A copy of the retail offer booklet will be available on the ASX on Thursday, 7 September 2023.

Key Dates

Key dates for the Entitlement Offer are as follows:

Event	Date (2023)
Trading halt - Placement and Institutional Entitlement Offer opens	Thursday, 31 August
Placement and Institutional Entitlement Offer closes	Friday, 1 September
Trading halt lifted, trading resumes on an ex-entitlement basis	Monday, 4 September
Record date for the Entitlement Offer	7:00pm (AEST) on Monday, 4 September
Settlement of shares issued under the Placement and Institutional Entitlement Offer	Thursday, 7 September
Retail Entitlement Offer opens, booklet and acceptance forms issued	Thursday, 7 September
Allotment and trading of New Shares issued under the Placement and Institutional Entitlement Offer	Friday, 8 September
Retail Entitlement Offer closes	5:00pm (AEST) on Thursday, 21 September

The above timetable is indicative only and subject to change.

If you have any questions in relation to the Entitlement Offer, please contact the Offer Information line on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia). For other questions, you should consult your broker, solicitor, accountant, financial adviser or other professional adviser.

Wilson's Corporate Finance Limited is acting as sole lead manager, bookrunner and underwriter to the Entitlement Offer.

TDM Growth Partners Pty Ltd (a major shareholder of the Company) and other existing institutional shareholders intend to subscribe for any shortfall of the Retail Entitlement Offer.



Terry Flitcroft
Company Secretary
SomnoMed Limited

Authorised for release to the ASX by Terry Flitcroft, Company Secretary

About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent[®] is the most comfortable and effective design and treatment solution for more than 810,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares to be offered and sold in the Entitlement Offer have not been, and will not be, registered under the United States Securities Act of 1933 (the **U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States.

Accordingly, the New Shares may not be offered or sold to persons in the United States, unless they have been registered under the U.S. Securities Act, or are offered and sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. This announcement contains such statements that are subject to risk factors associated with an investment in SomnoMed.